reported that a combination of CXCL9 gene therapy with low-dose cisplatin improved therapeutic efficacy in colon carcinoma (CT26) and Lewis lung carcinoma (LL/2c) murine models via inhibiting angiogenesis, augmenting CTL infiltration, and showed thymus-dependent antitumor effects (32). Here, CXCL9 is linked to colon carcinoma.